ICCM Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 0.66%, SMA50 -5.98%, SMA200 -29.9%). The stock’s 14-day RSI is 46.5 (neutral), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -60.57% below its high and over 9.59% above its low. Average 10-day trading volume of 713.37 thousand shares is slightly above the 3-month average of 565.72 thousand, indicating heightened recent market interest.

The stock is currently mid-range between its 52-week high and low $0.21 and $1.40. With a market capitalization of about $14.76 million, IceCure Medical Ltd is classified as a micro-cap and shows higher-than-market volatility (beta ~1.63). Key stats such as the average daily volume over the past year has been around 686.18 thousand shares, volume is running light vs its 52-week average. Headquartered in Caesarea, None, IceCure Medical Ltd operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Eyal Shamir, the company employs approximately 64 people and listed since August 26, 2021. IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body.

IceCure Medical Ltd generated EPS of -$0.26 over the past year. Five-year average earnings growth is 2.44%. Wall Street analysts project EPS growth of 9.25% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.05. Next year's EPS is expected at -$1.49. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $2.50 to $1.00. The high target offers 941.67% upside. The low target suggests 316.67% downside. The mean target is $1.83. This offers 662.5% upside. IceCure Medical Ltd earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 100.0%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include 14.29% in March 27, 2025.

IceCure Medical Ltd has 68.65 million shares outstanding. The public float is 37.89 million shares, elevated short interest at 34.96% of float. This equals 1.77 million shares. The short ratio is 0.79 days. Institutional investors hold 0.61% of the float. Insiders own 40.6%.

IceCure Medical Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.28. This means the shares are trading below this model’s fair value.

IceCure Medical Ltd trades at a P/E ratio of -1.09, slightly below the S&P 500 average, with a price-to-sales ratio of 4.18 and a price-to-book ratio of 2.03 suggesting the stock is closer to book value. The P/FCF stands at -0.97, also below market averages.

Our AI price prediction model suggests that IceCure Medical Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -23.63%, with price expected at $0.18 by June 03, 2026, within a range of $0.15 to $0.21 3-Month Outlook: Projected fall of -44.85%, reaching $0.13 by August 19, 2026, with a range of $0.10 to $0.16. 1-Year Outlook: Projected loss of -66.06%, with price at $0.08 by May 21, 2027, within a range of $0.00 to $0.00.

IceCure Medical Ltd (NASDAQ:ICCM) shares are flat 5.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows IceCure Medical Ltd trading at a premium to the broader market with a P/E of -1.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $2.66, suggesting 1028.55% upside. Our AI forecast model points to short-term weakness (-23.63% over two weeks), a medium-term fall (-44.85% over three months), and a longer-term loss (-66.06% over one year), with expected trading ranges indicating moderate volatility.